Market Cap 8.60M
Revenue (ttm) 0.00
Net Income (ttm) -24.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -2.88
Volume 412,400
Avg Vol 997,634
Day's Range N/A - N/A
Shares Out 53.29M
Stochastic %K 9%
Beta 2.96
Analysts Sell
Price Target $9.00

Company Profile

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 903 8354
Address:
3 Dublin Landings, North Wall Quay, Dublin, Ireland
Alder77
Alder77 Mar. 21 at 9:29 PM
$ITRM @Amb8675309 I'm writing it again so you can remember it. The drug will be successful, but it will already be owned by Pfizer, and Iterum will no longer exist. First delisting, then bankruptcy. Iterum no longer has any chance of survival or recovery. 👇🏼👇🏼👇🏼
0 ¡ Reply
Amb8675309
Amb8675309 Mar. 21 at 6:28 PM
$ITRM if ITRM is going to zero, put real money like Sabby. Show come courage. No more SDE
3 ¡ Reply
Amb8675309
Amb8675309 Mar. 21 at 6:26 PM
$ITRM what I find funny is all the negative people in here are all hat/ no cattle, as we say in Texas: posting day in/ day out and you’ve got $9500 on the line? Please…. If you can make money shorting the stock and you’ve got as much conviction as I do holding a serious long position, then grow a pair and put real money into it. What do they saying in the dating world? people that don’t want to commit they want a Situationship? If you like the business case for ITRM, make a commitment that reflects your research and conviction. if you dislike ITRM’s chances or think the company will fail, walk your talk. Make a big short bet. For you negative older posters here: saying you have invested for 30 years in biotech and every time you’re putting in $2500-come on-go drive for Uber/work part time at Costco. Otherwise you’re just a grumpy old keyboard warrior with small nutz.
1 ¡ Reply
Amb8675309
Amb8675309 Mar. 21 at 6:05 PM
$ITRM Pivya isn’t really competition
1 ¡ Reply
Biorocksme
Biorocksme Mar. 21 at 5:52 PM
$ITRM Pivya ——-Competition for sure—- With increasing emphasis on appropriate antibiotic stewardship and the need for effective firstline therapies, clinically established agents such as pivmecillinam are expected to play an important role in the management of uncomplicated urinary tract infections. The therapeutic category represents a large and stable market, accounting for approximately 30 million prescriptions annually in the US.
0 ¡ Reply
DollerADay
DollerADay Mar. 21 at 3:44 PM
$ITRM In laymans terms this means: the drug is: - chemically stable - accurately dosed - easy to test in production Combine that with the validation and adoption…🧨🚀
0 ¡ Reply
Biorocksme
Biorocksme Mar. 21 at 2:52 PM
$ITRM Pivya is available now https://www.biospace.com/press-releases/alembic-therapeutics-llc-announces-the-launch-of-pivya-pivmecillinam
3 ¡ Reply
gogo66so
gogo66so Mar. 21 at 10:51 AM
$ITRM A stability-indicating RP-HPLC method for simultaneous estimation of sulopenem etzadroxil and probenecid in bulk drug and combined tablet dosage form. March 16 2026 The stability-indicating character of the method was demonstrated through various forced degradation studies, where the produced degradants were distinctly separated from the peaks of Sulopenem Etzadroxil and Probenecid with good resolution, and the peak purity angle values were less than the purity threshold values, confirming the peak purity. The assay of a marketed formulation showed 99.64% and 99.93% of the labeled claim for Sulopenem Etzadroxil and Probenecid, respectively. The simple mobile phase and short run time made the method suitable for regular quality control and stability testing of Sulopenem Etzadroxil, and Probenecid in pharmaceutical industries. https://www.researchgate.net/publication/402468962_A_stability-indicating_RP-HPLC_method_for_simultaneous_estimation_of_sulopenem_etzadroxil_and_probenecid_in_bulk_drug_and_combined_tablet_dosage_form
1 ¡ Reply
Alder77
Alder77 Mar. 21 at 9:19 AM
$ITRM No one doubts that the drug works and will be successful. You still don't understand. Pfizer will be successful. Iterum has failed and can't continue. The argument is very simple. Iterum will be delisted and bankrupt, and the patent will be transferred to its true owner, Pfizer. Iterum will be used and will be a successful antibiotic. This success will not come from Iterum, where shareholders will receive zero.
1 ¡ Reply
Amb8675309
Amb8675309 Mar. 20 at 11:24 PM
$ITRM spent 58 minutes on phone with Alto today: lot of big clinics & specialty practices are writing Orlynvah for multiple different patients.Spoke with 2 pharmacists & 2 pharmacy techs. They’re telling me WAC is actually now $3500.. McKesson has a manufacturer hold because now Alto can deliver anywhere across the U.S. They will deliver it for free unless you want super expedited, then that’s a $10 fee. They ran my Aetna PPO through the system, they used my property addresses, my date of birth, all of it. Aetna PPO has NO prior auth and NO medical exception needed- if my doctor writes it, Aetna will cover it with a $100 co-pay. ITRM has a $75 online coupon they apply when filling script ➡️I pay $25. They’re seeing multiple scripts for different patients coming from specialty large practices(that’s the retention rate we like to see), that treat resistant uUTIs. Fed this into chat GPT➡️75% chance NASDAQ approves appeal, based on expanding scripts. Good Q1/26 launch numbers so far.DYODD
5 ¡ Reply
Latest News on ITRM
Iterum Therapeutics Provides Business Update

Feb 13, 2026, 8:00 AM EST - 5 weeks ago

Iterum Therapeutics Provides Business Update


Iterum Therapeutics Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 7:00 AM EST - 4 months ago

Iterum Therapeutics Reports Third Quarter 2025 Financial Results


Iterum Therapeutics to Present Data at IDWeek 2025

Oct 14, 2025, 8:30 AM EDT - 5 months ago

Iterum Therapeutics to Present Data at IDWeek 2025


Iterum Therapeutics Announces Extension of Term of Promissory Note

May 19, 2025, 7:00 AM EDT - 10 months ago

Iterum Therapeutics Announces Extension of Term of Promissory Note


Iterum Therapeutics Reports First Quarter 2025 Financial Results

May 13, 2025, 7:00 AM EDT - 11 months ago

Iterum Therapeutics Reports First Quarter 2025 Financial Results


Iterum Therapeutics Regains Full Nasdaq Compliance

Nov 21, 2024, 8:30 AM EST - 1 year ago

Iterum Therapeutics Regains Full Nasdaq Compliance


US FDA approves Iterum's treatment for urinary infection

Oct 25, 2024, 10:57 AM EDT - 1 year ago

US FDA approves Iterum's treatment for urinary infection


Iterum Therapeutics to Present Data at IDWeek 2024

Oct 10, 2024, 8:30 AM EDT - 1 year ago

Iterum Therapeutics to Present Data at IDWeek 2024


Iterum Therapeutics Commences Rights Offering

Jul 22, 2024, 7:30 AM EDT - 1 year ago

Iterum Therapeutics Commences Rights Offering


Iterum Therapeutics to Present Data at IDWeek 2023

Oct 12, 2023, 9:15 AM EDT - 2 years ago

Iterum Therapeutics to Present Data at IDWeek 2023


Iterum Therapeutics to Present Data at ASM Microbe 2023

Jun 12, 2023, 6:23 PM EDT - 3 years ago

Iterum Therapeutics to Present Data at ASM Microbe 2023


Alder77
Alder77 Mar. 21 at 9:29 PM
$ITRM @Amb8675309 I'm writing it again so you can remember it. The drug will be successful, but it will already be owned by Pfizer, and Iterum will no longer exist. First delisting, then bankruptcy. Iterum no longer has any chance of survival or recovery. 👇🏼👇🏼👇🏼
0 ¡ Reply
Amb8675309
Amb8675309 Mar. 21 at 6:28 PM
$ITRM if ITRM is going to zero, put real money like Sabby. Show come courage. No more SDE
3 ¡ Reply
Amb8675309
Amb8675309 Mar. 21 at 6:26 PM
$ITRM what I find funny is all the negative people in here are all hat/ no cattle, as we say in Texas: posting day in/ day out and you’ve got $9500 on the line? Please…. If you can make money shorting the stock and you’ve got as much conviction as I do holding a serious long position, then grow a pair and put real money into it. What do they saying in the dating world? people that don’t want to commit they want a Situationship? If you like the business case for ITRM, make a commitment that reflects your research and conviction. if you dislike ITRM’s chances or think the company will fail, walk your talk. Make a big short bet. For you negative older posters here: saying you have invested for 30 years in biotech and every time you’re putting in $2500-come on-go drive for Uber/work part time at Costco. Otherwise you’re just a grumpy old keyboard warrior with small nutz.
1 ¡ Reply
Amb8675309
Amb8675309 Mar. 21 at 6:05 PM
$ITRM Pivya isn’t really competition
1 ¡ Reply
Biorocksme
Biorocksme Mar. 21 at 5:52 PM
$ITRM Pivya ——-Competition for sure—- With increasing emphasis on appropriate antibiotic stewardship and the need for effective firstline therapies, clinically established agents such as pivmecillinam are expected to play an important role in the management of uncomplicated urinary tract infections. The therapeutic category represents a large and stable market, accounting for approximately 30 million prescriptions annually in the US.
0 ¡ Reply
DollerADay
DollerADay Mar. 21 at 3:44 PM
$ITRM In laymans terms this means: the drug is: - chemically stable - accurately dosed - easy to test in production Combine that with the validation and adoption…🧨🚀
0 ¡ Reply
Biorocksme
Biorocksme Mar. 21 at 2:52 PM
$ITRM Pivya is available now https://www.biospace.com/press-releases/alembic-therapeutics-llc-announces-the-launch-of-pivya-pivmecillinam
3 ¡ Reply
gogo66so
gogo66so Mar. 21 at 10:51 AM
$ITRM A stability-indicating RP-HPLC method for simultaneous estimation of sulopenem etzadroxil and probenecid in bulk drug and combined tablet dosage form. March 16 2026 The stability-indicating character of the method was demonstrated through various forced degradation studies, where the produced degradants were distinctly separated from the peaks of Sulopenem Etzadroxil and Probenecid with good resolution, and the peak purity angle values were less than the purity threshold values, confirming the peak purity. The assay of a marketed formulation showed 99.64% and 99.93% of the labeled claim for Sulopenem Etzadroxil and Probenecid, respectively. The simple mobile phase and short run time made the method suitable for regular quality control and stability testing of Sulopenem Etzadroxil, and Probenecid in pharmaceutical industries. https://www.researchgate.net/publication/402468962_A_stability-indicating_RP-HPLC_method_for_simultaneous_estimation_of_sulopenem_etzadroxil_and_probenecid_in_bulk_drug_and_combined_tablet_dosage_form
1 ¡ Reply
Alder77
Alder77 Mar. 21 at 9:19 AM
$ITRM No one doubts that the drug works and will be successful. You still don't understand. Pfizer will be successful. Iterum has failed and can't continue. The argument is very simple. Iterum will be delisted and bankrupt, and the patent will be transferred to its true owner, Pfizer. Iterum will be used and will be a successful antibiotic. This success will not come from Iterum, where shareholders will receive zero.
1 ¡ Reply
Amb8675309
Amb8675309 Mar. 20 at 11:24 PM
$ITRM spent 58 minutes on phone with Alto today: lot of big clinics & specialty practices are writing Orlynvah for multiple different patients.Spoke with 2 pharmacists & 2 pharmacy techs. They’re telling me WAC is actually now $3500.. McKesson has a manufacturer hold because now Alto can deliver anywhere across the U.S. They will deliver it for free unless you want super expedited, then that’s a $10 fee. They ran my Aetna PPO through the system, they used my property addresses, my date of birth, all of it. Aetna PPO has NO prior auth and NO medical exception needed- if my doctor writes it, Aetna will cover it with a $100 co-pay. ITRM has a $75 online coupon they apply when filling script ➡️I pay $25. They’re seeing multiple scripts for different patients coming from specialty large practices(that’s the retention rate we like to see), that treat resistant uUTIs. Fed this into chat GPT➡️75% chance NASDAQ approves appeal, based on expanding scripts. Good Q1/26 launch numbers so far.DYODD
5 ¡ Reply
Steloco1
Steloco1 Mar. 20 at 10:22 PM
$ITRM Me too 💵
0 ¡ Reply
Biorocksme
Biorocksme Mar. 20 at 8:53 PM
$ITRM It hasnt been the same around this joint since SolMike left 😢
1 ¡ Reply
YakoCapital
YakoCapital Mar. 20 at 8:43 PM
$ITRM Key dates (my best estimate, I don't have any inside info): 30 March - PR for Q4 ER 31 March - Q4 ER 18 April - PR on Nasdaq appeal (M&A or BK)
1 ¡ Reply
Amb8675309
Amb8675309 Mar. 20 at 7:59 PM
$ITRM adding
3 ¡ Reply
GatorMcKlusky
GatorMcKlusky Mar. 20 at 6:42 PM
$ITRM MASSIVE level manipulation occurring today. 75% of today's volume going to dark pool. Yet all that short volume hits the lit exchange. The never ending shakeout continues on. https://chartexchange.com/symbol/nasdaq-itrm/exchange-volume/
0 ¡ Reply
Alder77
Alder77 Mar. 20 at 6:35 PM
$ITRM You haven't gotten tired of making fun of yourselves. Besides, after more than a year, your embarrassing blunders are epochal and in black and white. You didn't even get your predictions right. That said, the only ones who haven't understood what's happening are you. The company is dead and will be delisted at the end of the month, early April at the latest. Just make your peace with it.
1 ¡ Reply
vic1torious
vic1torious Mar. 20 at 5:11 PM
$ITRM shitrm is dead give it up.
2 ¡ Reply
GatorMcKlusky
GatorMcKlusky Mar. 20 at 4:47 PM
$ITRM It's a shame more people don't understand how this manipulation works. This is the key right here. Stack those bids down below and move them up over time.
0 ¡ Reply
Immc
Immc Mar. 20 at 4:18 PM
$ITRM let me help yall out. This is AI view of the stock. Without prompts. Just is this going to fold.
2 ¡ Reply
GatorMcKlusky
GatorMcKlusky Mar. 20 at 4:15 PM
$ITRM So this is like deja vu all over again. Initial Deficiency (April 3, 2024): Iterum received a letter from Nasdaq stating it was out of compliance with the minimum stockholders' equity requirement of $2.5 million, reporting a deficit of over $6.4 million as of late 2023. Extension Granted (May 29, 2024): Nasdaq granted the company an extension until September 30, 2024, to regain compliance with the equity rule. Delisting Determination (October 1, 2024): After failing to meet the extension terms, Nasdaq issued a formal delisting determination letter. Hearing Request (October 9, 2024): Iterum appealed the decision, which temporarily stayed (paused) the delisting and allowed shares to continue trading under "ITRM" while a hearing was pending. Then we know what happened at the end of October 2024 launching this. Same script perhaps?
0 ¡ Reply
Biorocksme
Biorocksme Mar. 20 at 3:12 PM
May 25 $ITRM ipo Honey I shrunk the stock
1 ¡ Reply
Alder77
Alder77 Mar. 20 at 2:56 PM
$ITRM He's following all the steps just to give the impression that he's done everything. If he had done it openly, it would have been a clear fraud and he would have seriously risked jail time.
1 ¡ Reply